PRECLINICAL RESEARCH
Tumor Biomarkers Group

JOSEP VILLANUEVA

JOSEP VILLANUEVA
Principal Investigator
Biosketch

STRATEGIC GOALS

  • The characterization of mechanisms adopted by tumor cells to communicate with their microenvironment during tumorigenesis and targeted drug therapy. This data is then used for biomarker and drug target discovery.
  • Discovery of secreted signaling pathway-based tumor biomarkers and therapeutic targets using quantitative proteomics.
  • Characterize the influence of non-classical secretion during tumorigenesis, particularly in tumor invasion and metastasis.

TEAM

Tumor Biomarkers Group
  • Principal Investigator
    • Josep Villanueva
  • Post-doctoral Fellows
    • Merce Juliachs
    • Juan Manuel Duran
    • Olga Méndez
    • Nathalie Meo-Evoli
  • Graduate Student
    • Mireia Pujals
  •  Technicians
    • Ana Matres
    • Candida Salvans

Most relevant scientific publications

  • Méndez O, Villanueva J. Challenges and opportunities for cell line secretomes in cancer proteomics.Proteomics Clin Appl. 2015;9(3-4):348-357.
  • Katsila T, Juliachs M, Gregori J, Macarulla T, Villarreal L, Bardelli A, Torrance C, Elez E, Tabernero J, Villanueva J. Circulating pEGFR is a candidate response biomarker of cetuximab therapy in colorectal cancer. Clin. Cancer Res. 2014 Dec; 20(24): 6346-56
  • Villarreal L, Méndez O, Salvans C, Gregori J, Baselga J, Villanueva J*. Unconventionalsecretion is a major contributor of cancer cell line secretomes. Mol Cell Proteomics. 2013, 12(5):1046-60.
  • Gregori J, Méndez O, Katsila T, Pujals M, Salvans C, Villarreal L, Arribas J, Tabernero J, Sánchez A, Villanueva J. Enhancing the Biological Relevance of Secretome-Based Proteomics by Linking Tumor Cell Proliferation and Protein Secretion. J. Proteome Res. 2014 Jul;
  • Gregori J, Villarreal L, Sánchez A, Baselga J, Villanueva J. An effect size filter improves the reproducibility in spectral counting-based comparative proteomics. J Proteomics 2013 Dec; 95: 55-65
  • Gregori J, Villarreal L, Méndez O, Sánchez A, Baselga J, Villanueva J. Batch effects correction improves the sensitivity of significance tests in spectral counting-based comparative discovery proteomics. J Proteomics 2012 Jul; 75(13): 3938-51
  • Lawlor K, Nazarian A, Lacomis L, Tempst P, Villanueva J*. Pathway-based biomarker search by high-throughput proteomics profiling of secretomes. J Proteome Research. 2009. 8(3):1489-503.

All publications

  • Zacarias-Fluck MF, Morancho B, Vicario R, Luque Garcia A, Escorihuela M, Villanueva J, Rubio IT, Arribas J.  Effect of cellular senescence on the growth of HER2-positive breast cancers. J. Natl. Cancer Inst. 2015 May; 107(5)
  • Morancho B, Martínez-Barriocanal Á, Villanueva J, Arribas J.  Role of ADAM17 in the non-cell autonomous effects of oncogene-induced senescence. Breast Cancer Res. 2015; 17: 106
  • Katsila T, Juliachs M, Gregori J, Macarulla T, Villarreal L, Bardelli A, Torrance C, Elez E, Tabernero J, Villanueva J.  Circulating pEGFR is a candidate response biomarker of cetuximab therapy in colorectal cancer. Clin. Cancer Res. 2014 Dec; 20(24): 6346-56
  • Nazarian A, Lawlor K, Yi SS, Philip J, Ghosh M, Yaneva M, Villanueva J, Saghatelian A, Assel M, Vickers AJ, Eastham JA, Scher HI, Carver BS, Lilja H, Tempst P.  Inhibition of circulating dipeptidyl peptidase 4 activity in patients with metastatic prostate cancer. Mol. Cell Proteomics 2014 Nov; 13(11): 3082-96
  • Gregori J, Méndez O, Katsila T, Pujals M, Salvans C, Villarreal L, Arribas J, Tabernero J, Sánchez A, Villanueva J.  Enhancing the Biological Relevance of Secretome-Based Proteomics by Linking Tumor Cell Proliferation and Protein Secretion. J. Proteome Res. 2014 Jul;
  • Segura V, Medina-Aunon JA, Mora MI, Martínez-Bartolomé S, Abian J, Aloria K, Antúnez O, Arizmendi JM, Azkargorta M, Barceló-Batllori S, Beaskoetxea J, Bech-Serra JJ, Blanco F, Monteiro MB, Cáceres D, Canals F, Carrascal M, Casal JI, Clemente F, Colomé N, Dasilva N, Díaz P, Elortza F, Fernández-Puente P, Fuentes M, Gallardo O, Gharbi SI, Gil C, González-Tejedo C, Hernáez ML, Lombardía M, Lopez-Lucendo M, Marcilla M, Mato JM, Mendes M, Oliveira E, Orera I, Pascual-Montano A, Prieto G, Ruiz-Romero C, Sánchez del Pino MM, Tabas-Madrid D, Valero ML, Vialas V, Villanueva J, Albar JP, Corrales FJ.  Surfing transcriptomic landscapes. A step beyond the annotation of chromosome 16 proteome. J. Proteome Res. 2014 Jan; 13(1): 158-72
  • Gregori J, Villarreal L, Sánchez A, Baselga J, Villanueva J.  An effect size filter improves the reproducibility in spectral counting-based comparative proteomics. J Proteomics 2013 Dec; 95: 55-65
  • Angelini PD, Zacarias Fluck MF, Pedersen K, Parra-Palau JL, Guiu M, Bernadó Morales C, Vicario R, Luque-García A, Navalpotro NP, Giralt J, Canals F, Gomis RR, Tabernero J, Baselga J, Villanueva J, Arribas J.  Constitutive HER2 signaling promotes breast cancer metastasis through cellular senescence.Cancer Res. 2013 Jan; 73(1): 450-8
  • Gregori J, Villarreal L, Méndez O, Sánchez A, Baselga J, Villanueva J.  Batch effects correction improves the sensitivity of significance tests in spectral counting-based comparative discovery proteomics. J Proteomics 2012 Jul; 75(13): 3938-51
  • Sánchez A, Villanueva J.  PI3K-based molecular signatures link high PI3K pathway activity with low ER levels in ER+ breast cancer. Expert Rev Proteomics 2010 Dec; 7(6): 819-21
  • Villanueva J, Nazarian A, Lawlor K, Tempst P.  Monitoring peptidase activities in complex proteomes by MALDI-TOF mass spectrometry. Nat Protoc 2009; 4(8): 1167-83
  • Lawlor K, Nazarian A, Lacomis L, Tempst P, Villanueva J.  Pathway-based biomarker search by high-throughput proteomics profiling of secretomes. J. Proteome Res. 2009 Mar; 8(3): 1489-503
  • Villanueva J, Nazarian A, Lawlor K, Yi SS, Robbins RJ, Tempst P.  A sequence-specific exopeptidase activity test (SSEAT) for “functional” biomarker discovery. Mol. Cell Proteomics 2008 Mar; 7(3): 509-18
  • Villanueva J, Philip J, DeNoyer L, Tempst P.  Data analysis of assorted serum peptidome profiles. Nat Protoc 2007; 2(3): 588-602
  • Villanueva J, Lawlor K, Toledo-Crow R, Tempst P.  Automated serum peptide profiling. Nat Protoc 2006; 1(2): 880-91
  • Villanueva J, Martorella AJ, Lawlor K, Philip J, Fleisher M, Robbins RJ, Tempst P.  Serum peptidome patterns that distinguish metastatic thyroid carcinoma from cancer-free controls are unbiased by gender and age. Mol. Cell Proteomics 2006 Oct; 5(10): 1840-52
  • Villanueva J, Shaffer DR, Philip J, Chaparro CA, Erdjument-Bromage H, Olshen AB, Fleisher M, Lilja H, Brogi E, Boyd J, Sánchez-Carbayo M, Holland EC, Cordon-Cardo C, Scher HI, Tempst P. Differential exoprotease activities confer tumor-specific serum peptidome patterns. J. Clin. Invest. 2006 Jan; 116(1): 271-84
  • Villanueva J, Philip J, Entenberg D, Chaparro CA, Tanwar MK, Holland EC, Tempst P.  Serum peptide profiling by magnetic particle-assisted, automated sample processing and MALDI-TOF mass spectrometry. Anal. Chem. 2004 Mar; 76(6): 1560-70